KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EPS (Weighted Average and Diluted) (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of EPS (Weighted Average and Diluted) data on record, last reported at -$5.57 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 33.57% year-over-year to -$5.57; the TTM value through Dec 2025 reached -$2.91, down 1555.0%, while the annual FY2025 figure was -$2.91, 1555.0% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$5.57 in Q4 2025 per CRL's latest filing, down from $1.1 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.65 in Q4 2022 and bottomed at -$5.57 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.18, with a median of $1.74 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 50.83% in 2022, then tumbled 214.56% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.67 in 2021, then soared by 36.7% to $3.65 in 2022, then fell by 0.27% to $3.64 in 2023, then crashed by 214.56% to -$4.17 in 2024, then plummeted by 33.57% to -$5.57 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$5.57 in Q4 2025, $1.1 in Q3 2025, and $1.06 in Q2 2025.